Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has shared an update.
Targovax ASA has extended its financing commitment with Atlas to ensure operational funding through the end of 2025. This additional financing, involving convertible bonds, provides the company with greater flexibility and supports its ongoing development programs, potentially strengthening its position in the biotechnology industry.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for advanced gene and cell therapies. The company has developed the circVec platform, which enhances RNA and protein expression for various therapeutic applications, including genetic medicine and cell therapy. Circio also continues its immuno-oncology program, TG01, targeting RAS-mutated cancers.
YTD Price Performance: -12.68%
Average Trading Volume: 873,869
Current Market Cap: NOK65.42M
For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.